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Abstract
Background: The Evaluation of pimobendan in dogs with cardiomegaly caused by
preclinical myxomatous mitral valve disease (EPIC) study monitored dogs with myxo-
matous mitral valve disease (MMVD) as they developed congestive heart fail-
ure (CHF).
Objectives: To describe the changes in clinical and radiographic variables occurring
as dogs with MMVD and cardiomegaly develop CHF, compared to similar dogs that
do not develop CHF.
Animals: One hundred and thirty-five, and 73 dogs that did or did not develop CHF,
respectively.
Materials and methods: The following variables were evaluated in 2 groups of dogs
(dogs that did or did not develop CHF): Heart rate (HR), clinic respiratory rate (RR),
home-measured resting respiratory rate (RRR), rectal temperature (RT), body weight
(BW), and vertebral heart sum (VHS). Absolute value and rate of change of each vari-
able were calculated for each day a dog was in study. Daily means were calculated
and plotted against time. The onset of CHF or last visit before leaving the study were
set as reference time points.
Results: The most extreme values and rate of change occurred in variables immedi-
ately before onset of CHF. Vertebral heart sum increased earliest. Heart rate, RR, and
RRR also increased. Rectal temperature and BW decreased. Increases in RR and RRR
were most extreme and occurred immediately before CHF.
Conclusions and Clinical Importance: Dogs with MMVD and cardiomegaly experi-
ence increases in HR, RR, RRR, and VHS, and decreases in BW and RT as they
develop CHF. The variables with highest absolute change and rate of change were
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RR and RRR. These findings reinforce the value of RR and RRR as indicators of
impending or incipient CHF.
K E YWORD S
canine, cardiovascular, clinical epidemiology, clinical trials, heart failure, physical examination,
radiology and diagnostic imaging
1 | INTRODUCTION
The “Evaluation of pimobendan in dogs with cardiomegaly caused by
preclinical myxomatous mitral valve disease” (EPIC) study was a multi-
center, blinded, randomized, placebo-controlled clinical trial evaluating
the effect of pimobendan in delaying the onset of clinical signs in dogs
with cardiac enlargement secondary to myxomatous mitral valve dis-
ease (MMVD). The main findings and longitudinal results have been
published previously.1,2 Longitudinal analysis indicated that a number
of clinical, laboratory, radiographic, and echocardiographic variables
changed significantly as dogs developed heart failure.1 Dogs receiving
pimobendan were indistinguishable from those receiving placebo at
the time of the onset of congestive heart failure (CHF).1
Previous studies have identified not only the absolute changes in
clinical, radiographic, and echocardiographic variables in patients with
progressive MMVD, but the time course over which these changes
occur. One study documented the change in vertebral heart sum
(VHS) that occurred in Cavalier King Charles Spaniels before the onset
of CHF.3 The change in heart size occurred over approximately 1 year
and was maximal immediately before the onset of CHF.4 Longitudinal
changes in echocardiographic indicators of heart size,5 heart rate (HR),
and heart rate variability6 before patients succumb to MMVD indicate
a similar pattern with an increasing rate of change of the monitored
variables as the disease progresses. The increase in heart size before
the onset of CHF occurs so consistently that heart size has been vali-
dated as a component of a regression equation that can be used with
reasonable accuracy to predict the onset of CHF.7 Dogs developing
CHF in the EPIC study showed increased heart size and HR at the time
of onset of CHF compared to measurements made at baseline.1
Respiratory rate (RR), measured in the clinic, and client-measured
resting respiratory rate (RRR), measured in the dog's home environment,
have been shown to be higher in dogs in CHF8,9 returning to more nor-
mal values once signs of heart failure are medically controlled.10 The
longitudinal change in RR and RRR in a large population of dogs as they
develop CHF has not been described previously. Dogs with preclinical
left-sided heart disease have been shown to have a RRR that usually is
<25 breaths per minute.11 Respiratory rate measured in the clinic was
significantly higher at the time of onset of CHF in dogs in the EPIC
study compared to results obtained at baseline. The RRR measured by
owners in the home environment was not available at the baseline visit
for comparison with results obtained immediately before CHF.1
As well as the previously reported changes in HR, heart size, and
RR, dogs in the EPIC study that developed CHF experienced decreases
in rectal temperature and body weight as they developed CHF.1
In the EPIC study, over 100 dogs were monitored as they devel-
oped CHF.2 Data from this population therefore provide a unique
opportunity to determine not only the magnitude of the change in
clinical and radiographic variables as CHF develops, but the time
course over which those changes occur.
The aim of our current study is to describe, in a group of dogs
with stage B212 MMVD, the temporal changes in clinical and radio-
graphic variables that occur before development of CHF and to con-
trast the changes in dogs that developed CHF to a population of dogs
known not to have developed CHF over the duration of the study.
2 | MATERIALS AND METHODS
2.1 | Trial design
The EPIC trial was a prospective multicenter, blinded, randomized,
placebo-controlled study. Complete and detailed description of the study
and longitudinal changes in measured variables have been published.1,2
The study was approved by an ethical review committee at each site
where this was required.
2.2 | Dogs
2.2.1 | Enrollment criteria
Dogs were eligible for participation in the study provided the owner had
given informed consent. To be eligible for inclusion, a dog had to be
≥6 years of age, have a body weight (BW) ≥4.1 and ≤15 kg, have
a characteristic systolic heart murmur of moderate-to-high intensity (grade
≥ 3/6) with maximal intensity over the mitral area, have echocardiographic
evidence of advanced MMVD defined as characteristic valvular lesions of
the mitral valve apparatus, mitral regurgitation (MR) on the color Doppler
echocardiogram, and have echocardiographic and radiographic evidence
of cardiomegaly defined as a left atrial-to-aortic root ratio (LA/Ao) ≥1.6
measured in a short-axis view,13 BW-normalized left ventricular internal
diameter in diastole (LVIDDN)14 ≥1.7 and a VHS >10.5.15
2.2.2 | Exclusion criteria
Dogs were excluded from the study if they had any of the following:
known clinically important systemic or other organ-related disease
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that was expected to limit the dog's life expectancy or required
chronic administration of cardiovascular medication precluded as part
of the trial. Dogs with hypothyroidism could be included provided the
investigator deemed them clinically stable on treatment. Dogs with
current or previous evidence of cardiogenic pulmonary edema, pulmo-
nary venous congestion or both, cardiac disease other than MMVD,
clinically significant supraventricular, ventricular tachyarrhythmias or
both (ie, requiring antiarrhythmic treatment), or evidence of pulmo-
nary hypertension considered to be clinically relevant (right ventricu-
lar: right atrial pressure gradient >65 mmHg) were excluded. Dogs
with a history of chronic or recent administration (>14 days of dura-
tion or within 30 days of intended enrollment) of any precluded medi-
cation were excluded. In the event that, before study enrollment, a
dog had received short-term treatment (<14 days) with a precluded
agent, but was no longer receiving treatment and had not received it
within 30 days of intended enrollment, then the dog was eligible for
inclusion. Dogs that were pregnant or lactating were not eligible for
enrollment.
Details of study sites, randomization and blinding, trial medication,
concomitant treatment, and data management have been described
previously.2
2.2.3 | Schedule of events
Before inclusion, a case history was taken for each dog. At a baseline visit,
dogs underwent physical examination, echocardiography, thoracic radiog-
raphy, and routine hematology and blood biochemistry. Reexaminations
were scheduled at 35 days after the baseline visit, approximately
4 months after baseline and every 4 months thereafter. Details of exam-
inations that were undertaken on each visit are provided in Table 1.
2.2.4 | Clinical evaluation
At inclusion, dog characteristics such as breed, age, sex, and neuter
status were noted. The BW, HR, RR, and rectal temperature (RT) were
measured at each visit.
2.2.5 | Thoracic radiography
Thoracic radiography was performed at the baseline visit, 8 months
after baseline and every 8 months thereafter for as long as the dog
remained in the per-protocol population. It also was performed at the
time a dog was considered to have developed signs of CHF. Right lat-
eral and dorsoventral projections were used to evaluate the thorax.
Cardiac size was assessed by the VHS method,15 and pulmonary
edema and congestion were recorded, when considered to be present,
by the attending cardiologist.
2.2.6 | Resting respiratory rate
Owners also were asked to measure RRR before every reexamination.
Instruction was provided to owners who were advised to count the
TABLE 1 Schedule of procedures undergone by animals remaining in the per-protocol population of the study at different examinations
Baseline visit Baseline +35 days (±7 days) Baseline +4 monthsa Baseline +8 monthsb Event
Physical examination X X X X X
Thoracic radiograph X X X
Owner measured respiratory rate X X X X
aFour months from baseline visit and every 8 months thereafter.
bEight months from baseline visit and every 8 months thereafter.
F IGURE 1 The method of calculation of
imputed values of continuous variables and the
rate of change of variables
4 BOSWOOD ET AL.
respiratory rate over 1 minute, in the dog's home environment, within
the week before each reexamination. Ideally, determination was per-
formed on several days and the average of the measurements obtained
was recorded as a single value at the corresponding visit.
2.2.7 | Primary endpoint
The primary endpoint was a composite of the development of left-
sided CHF verified by an endpoint committee,2 euthanasia for a car-
diac reason, or death presumed to be cardiac in origin.
2.3 | Statistical methods
For those dogs with verified CHF (Group CHF), the day of confirmed
CHF was considered day 0. The day of measurement of different vari-
ables was expressed as the number of days before day 0. For example,
if a measurement was taken 7 days before the onset of CHF, this day
would be considered day −7.
For comparison, a group of dogs that were known not to have
developed CHF (Group no-CHF) for at least 4 months after their final
examination were included. This group consisted of dogs that were
censored at the time of study closure that were known not to have
experienced CHF by that time (March 1, 2015), and for which suffi-
cient data were available to contribute to the analyses. Day 0 for no-
CHF dogs was defined as the day of the last visit on which all radio-
graphic and clinical examination data were obtained (see Table 1) that
was at least 4 months before closure of the study.
The values for BW were indexed to the baseline value of this vari-
able because of the large range of values seen in the population.
Indexing was performed according to the formula 100 × (observed
BW [kg])/(BW baseline [kg]). Therefore, dogs that experienced weight
loss would have values less than 100.
Observations were evaluated for plausibility. All respiratory rate
(RR and RRR) observations ≥100/min were assumed to represent
panting and were removed from analyses.
For the 6 continuous variables recorded at least once in every
8-month period throughout the study (HR, RR, RRR, RT, BW, and
VHS) for which at least 2 measurements at different time points were
available for any given dog, the following were calculated: An absolute
TABLE 2 Baseline characteristics of the Group CHF and Group no-CHF
Variable
Group
CHF, N = 135 No-CHF, N = 73
Dog
characteristics
Proportion on pimobendan versus placebo (%) Pimobendan = 59 (43.7%)
Placebo = 76 (56.3%)
Pimobendan = 50 (68.5%)
Placebo = 23 (31.5%)
Age (years) 9.0 (7.0-11.0) 9.0 (7.0-10.0)
Sex (M/F/MC/FS) (%) 17.8/4.4/43.0/34.8 26.0/5.5/35.6/32.9
Breed (CKCS/Yorkshire terrier
Dachshund/Poodle/Miniature
Schnauzer/mixed breed/other breeds) (%)
45.9/2.2/5.9/3.0/3.0/11.1/28.9 45.2/1.4/4.1/2.7/5.5/6.8/34.2
Physical
Examination
Body weight (kg) 9.0 (7.2-10.7) 8.3 (6.3-10.4)
Resting respiratory rate (breaths per min if <100) 23 (19-28) [N = 120] 21 (18-26) [N = 71]
Respiratory rate (breaths per min if <100) 30 (24-36) [N = 127] 28 (24-36) [N = 67]
Heart rate (BPM) 128 (111-140) 120 (106-140)
Rectal temperature (C) 38.7 (38.4-39.1) 38.7 (38.4–39.1) [N = 71]
Diagnostic
Imaging
Vertebral heart sum 11.4 (11.0-12.0) [N = 134] 11.5 (11.0-12.0)
Note: Continuous variables are reported as median (interquartile range). Categorical variables are reported as number (%). The number of observations is
reported for variables where it is different to the reported number of dogs in the group.
F IGURE 2 The rate of change of vertebral heart sum in dogs in
the CHF group separated according to the treatment they were
receiving
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value of the variable for each dog on any day between 2 observations
was calculated by interpolation for the days on which the value was
not known. Absolute values of variables between visits were
calculated by plotting values obtained at each visit against time
for each dog, assuming a linear rate of change, and interpolating
values from the plotted line to give the value of that variable for
F IGURE 3 A, Percent of baseline bodyweight (BW) in the 2 groups over the 18 months before day 0. B, Clinic measured respiratory rate
(RR) in the two groups over the 18 months before day 0. C, Heart rate (HR) in the 2 groups over the 18 months before day 0. D, Owner measured
resting respiratory rate (RRR) in the 2 groups over the 18 months before day 0. E, Rectal temperature (RT) in the 2 groups over the 18 months
before day 0. F, Vertebral heart sum (VHS) in the 2 groups over the 18 months before day 0
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each intervening day. The rate of change of the variable was
calculated for each day a dog was in the study as illustrated in
Figure 1. The rate of change was assumed to be constant between
2 observations.
The daily mean of the absolute values and the daily rate of
change for each group (CHF and no-CHF) were calculated for each
day and plotted against time. Values for rate of change were
expressed as the rate of change per month, calculated by multiplying
the daily rate of change by 30. These were plotted initially by treat-
ment group (pimobendan and placebo) and with data from dogs in
both treatment groups pooled. Graphs display the curves for the
18 months (540 days) evaluated before day 0.
F IGURE 4 A, Rate of change (Roc) of bodyweight (BW) in the 2 groups over the 18 months before day 0. B, Roc of clinic measured
respiratory rate (RR) in the 2 groups over the 18 months before day 0. C, Roc of heart rate (HR) in the 2 groups over the 18 months before day
0. D, Roc of owner measured resting respiratory rate (RRR) in the 2 groups over the 18 months before day 0. E, Roc of rectal temperature (RT) in
the 2 groups over the 18 months before day 0. F, Roc of vertebral heart sum (VHS) in the 2 groups over the 18 months before day 0
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Finally, for the CHF group, to illustrate the temporal relationships
between the different changes observed, the rates of change were
expressed as a percentage of the maximum rate of change for each
variable. Variables that increased with time were plotted on 1 set of
axes. Variables that decreased with time were plotted on a different
set of axes. No inferential statistics were performed.
3 | RESULTS
3.1 | Dogs
Over the duration of the study, 135 dogs experienced an onset of
CHF and were included in the CHF group. Of the dogs in the CHF
group, 59 were receiving pimobendan and 76 placebo.
The no-CHF group consisted of 73 dogs. Of the dogs in the no-
CHF group, 50 were receiving pimobendan and 23 placebo. The
median time in study for the CHF dogs was 414 days (interquartile
range [IQR] 242-729 days). The median time in study for the no-CHF
dogs was 1055 days (IQR, 976-1221 days).
The baseline characteristics of the 2 groups are summarized in
Table 2. Twenty-eight from a total of 951 observations (2.9%) of RR
were ≥100 breaths per minute and therefore were excluded from
analyses. Twenty-five of these excluded observations were made in
18 dogs in the CHF group (4.0% of all observations in this group). In
only 4 instances were these excluded observations made at the time
of onset of CHF. Three RR observations were excluded in 3 dogs in
the no-CHF group (0.9% of all observations in this group). In none
of these instances were the excluded observations made at the final
visit. Three from a total of 859 observations of RRR were ≥100
breaths per minute and therefore were excluded from analyses. All
3 observations were in the CHF group representing 0.6% of all
observations in this group. All 3 observations corresponded to the
visit at which CHF was diagnosed. One dog in the CHF group was
excluded from analyses of VHS as consequence of there being a
single obvious outlying data point where the magnitude of change
over consecutive measurements was considered more likely to be
attributable to a measurement or entry error rather than to genuine
progression of disease.
3.2 | Continuous variables and their rate of change
In all instances, visual inspection of plots showing absolute change
and rate of change in the 6 studied variables in dogs receiving
pimobendan or placebo suggested that, within the CHF group and the
no-CHF group, the pimobendan and placebo groups did not behave
differently. This is illustrated for the rate of change of VHS in the CHF
group in Figure 2 (similar graphs illustrating the rate of change for the
CHF population in the 2 treatment groups are available in Figure S1A-
E). All other displayed graphs are derived from data pooling both
treatment groups (pimobendan and placebo) within each group (group
CHF and group no-CHF).
The absolute values of the 6 studied variables for the CHF and
no-CHF dogs are shown in Figure 3A-F. Body weight remained at
approximately 100% of baseline for both groups until approximately
4 months before day 0. In the CHF group, mean BW decreased by
approximately 3.5% in the 4 months before day 0. No similar change
was seen in the non-CHF group. Mean RR remained similar at approx-
imately 31 breaths per minute in both groups until 4 months before
F IGURE 5 Percent of the maximum rate of change for the
4 variables that increased over time expressed against time in the
18 months up to and including day 0
F IGURE 6 Percent of the maximum rate of change for the
2 variables that decreased over time expressed against time in the
18 months up to and including day 0
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day 0. In the CHF group, the mean RR then increased to 49 breaths
per minute by day 0 while remaining approximately 30 breaths per
minute in the non-CHF group. Mean RRR was in the low 20s in both
groups until approximately 4 months before day 0. Over the last
4 months, mean RRR increased to approximately 40 breaths per
minute in the CHF group while remaining constant in the non-CHF
group. Mean HR was approximately 125 bpm in both groups until
about 10 months before day 0. Over the 10 months before day 0, it
increased to approximately 150 bpm in the CHF group while
remaining at approximately 125 in the non-CHF group. Mean RT was
approximately 38.6C in both groups until the final 2 months before
CHF. In the last 2 months, RT decreased by approximately 0.2C in
the CHF group while remaining 38.6C in the non-CHF group. Finally,
mean VHS initially was approximately 11.5 in both groups. In the CHF
group the mean VHS gradually increased over the 12 months before
day 0 to 12.9 at the onset of CHF. In the non-CHF group, VHS did
not change over the 18-month period.
The rate of change per month of the 6 studied variables is shown
in Figure 4A-F. The temporal relationship of the maximum change of
the 4 studied variables in the CHF dogs that increased is shown in
Figure 5. The temporal relationship of the maximum change of the
2 variables in the CHF dogs that decreased is shown in Figure 6. For
all variables, the maximal rate of change was observed in the period
immediately before the onset of CHF.
4 | DISCUSSION
Ours is the first study to demonstrate the time course over which
changes in several clinical variables occur in dogs with MMVD as they
progress into CHF. The changes that occurred in these variables were
contrasted to those that occurred over a similar time period in dogs
known not to have developed CHF.
Our study showed that all evaluated variables (HR, RR, RRR, RT,
BW and VHS) changed in MMVD stage B2 dogs as they developed
CHF. Similar changes were not observed in dogs that did not progress
into CHF.
The most striking changes in any of the variables were found in
RR and RRR. These increased from baseline values of approximately
31 and 23 per minute, respectively, to 49 and 41 per minute at the
onset of CHF. These changes represent increases of 58 and 78% of
the baseline value, respectively. The RRR values generally were lower
than the RR, presumably as a consequence that RR were measured at
the clinic and under more stressful circumstances. Previous studies
have shown that RRR >30 breaths per minute in home environment11
or RR >40 breaths per minute in clinic environment9 are strong indica-
tors for the presence of active CHF in MMVD dogs without any other
important comorbidity. Our findings agree with these cutoffs and
show that RR and RRR are comparably stable during the progression
into CHF until late stages. Both RR and RRR only appeared to change
within the 4 months immediately before the onset of CHF and
showed little variation before that time. It is also interesting to note
that a lower proportion of values for RRR were excluded from
analyses because of presumed panting. This may suggest that mea-
sures of RRR are less likely to be confounded by panting and, being
obtained by averages obtained over several days, are less prone to
being affected by outlying observations.
A nonlinear increase in VHS previously has been described in
dogs and the findings of the present study agree with these studies3,4
(ie, the changes were characterized by a gradual increase over time
until 6-12 months before confirmed CHF when average VHS changed
rapidly from approximately 11.5 to almost 13.0, representing an
approximate increase of 15%). This increase in VHS represents an
increase in heart size probably brought about by worsening volume
overload and worsening of MR. The latter may be caused by worsen-
ing of the myxomatous changes in the valve leaflets, cardiac dilatation
itself, and possibly chordal ruptures of the mitral valve.
Heart rate previously has been shown to increase over time in
MMVD dogs as they progress into CHF.6,16 In our study, small
increases in HR could be seen from 10 months before confirmed
CHF, but no such change could be observed in dogs not progressing
to CHF within 4 months of the last examination. Mean heart rate
increased from approximately 125 to 150 beats per minute, rep-
resenting a change of 20% from the baseline value. The increase in
HR probably is brought about by a response to worsening MR causing
a decrease in forward stroke volume, which is compensated by
increased sympathetic tone leading to increased HR.17,18
Body weight and RT both decreased over time as dogs prog-
ressed into CHF. The decrease in RT is likely to be a consequence of
impaired peripheral perfusion.19 The decrease in BW may be a conse-
quence of the loss of skeletal muscle mass, but we did not record
body condition or muscle condition scores at each visit and therefore
cannot be sure of this conclusion. Loss of muscle mass may occur as a
consequence of cardiac cachexia.20 Cardiac cachexia is a complex syn-
drome that may be, at least in part, a consequence of systemic inflam-
mation21 and intestinal underperfusion.22 Furthermore, during the
development of CHF, dogs may show evidence of a decreased appe-
tite, which will decrease calorie intake and predispose to weight
loss.20 Decreased appetite previously has been associated with worse
outcome, both in the present study population of EPIC trial dogs2 and
other studies.23 Cardiac cachexia has been associated with shorter
survival times in dogs with heart disease.21,24
The magnitude of the change observed in both BW and RT
were comparably small in relation to the natural variability
observed; an approximately 3% change in BW and 0.2C change in
RT. This observation indicates that, although these changes were
evident on a population level, they are very unlikely to be detect-
able in an individual dog. A previous study reported a difference in
RT of 0.3C between dogs in stages B2 and C of MMVD, however
the difference observed was not significant, perhaps because of
the low number of dogs in the study.19 Although some definitions
of cachexia require the loss of 5% of a dog's BW for it to be con-
sidered cachexic,21 our findings suggest that smaller decreases in
BW are common in dogs developing CHF and not seen in dogs
that do not develop CHF. It seems likely that similar mechanisms
underlie the observed weight loss in these dogs.
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The most important findings of our study illustrate the temporal
evolution of the observed changes in the studied variables in MMVD
stage B2 dogs before the onset of confirmed CHF. For all of the 6 vari-
ables evaluated, the rate of change of the variable was maximal in the
period immediately before the onset of CHF (Figures 5 and 6).
Although rate of change increased in VHS the closer in time the dogs
were to CHF, the change was gradual over time compared to changes
in the other variables and seemed to be evident at least 1 year before
the onset of CHF. By contrast, the changes in BW, HR, RT, RR, and
RRR occurred late in the process (ie, within the last few months
before confirmed CHF). The magnitude and timing of the increase in
respiratory rate variables reinforces the value of these variables as
indicators of impending or incipient CHF.
4.1 | Limitations
Not all dogs enrolled in the EPIC trial were included in the present
study. The main group of interest consisted of only those dogs that
progressed into verified CHF during the study. For comparison, we
chose to characterize changes over a similar period in dogs that were
known not to have developed CHF for at least 4 months after their final
examination. The reason for the latter was to ensure that dogs in the
comparison group could not have developed CHF shortly after their
final examination. Dogs reaching the primary endpoint for reasons
other than developing CHF were not included in the analysis. Dogs cen-
sored for reasons other than still being alive at the end of the study
were not included because reasons for censoring these dogs could be
associated with the possible development of CHF that was not verified
as a primary endpoint (eg, because of administration of unauthorized
drugs). Choosing to contrast the changes in the 2 extremes of the popu-
lation (those that developed CHF and those that definitely did not) may
exaggerate the observed differences and such clear contrasts may not
be observed in a more heterogenous population.
In the present study, the maximum duration of time over which
variables were described was 18 months. Many dogs, particularly
those in the no-CHF group, spent longer in the study, but the reason
for selecting 18 months was that larger numbers of dogs could con-
tribute observations over the entirety of this period leading to more
precise estimates of variables.
Our study was limited to characterizing the changes in only 6 con-
tinuous variables. The reason for this limitation was that these were the
only continuous variables measured at least once in every 8-month
period throughout the study. Accordingly, the study cannot characterize
changes in other potential variables of interest, such as heart murmur
intensity, echocardiographic findings, blood pressure, and biomarker
concentrations.
The frequency of measured variables was limited to every 4 months
for the clinical variables and every 8 months for VHS measurement.
The changes occurring between these points of measurements there-
fore are unknown. Furthermore, not all intervals were standardized,
because some visits at which variables were assessed were emergency
visits rather than visits scheduled in the protocol.
We described the mean value and mean rate of change in the
6 variables we have evaluated. Within a population of dogs, variability
will exist in the absolute values and their rates of change. We have
not attempted to perform subanalyses or to identify populations that
may have different rates of change such as those in which ruptured
chordae tendinae may cause sudden development of CHF in the
absence of a marked increase in heart size.
As shown in Figure 1, our method of imputing values of variables
assumed a linear rate of change of those variables between true obser-
vations, but our analyses indicate that the rate of change was not linear.
This situation may have resulted in an underestimate of the rate of
change of variables at the end of periods between observations and an
overestimate of the rate of change at the beginning of periods between
observations. The overall effect on the absolute values of variables cal-
culated may have been to conclude that values increased sooner than
would have truly been observed had they been measured more fre-
quently. This may mean that changes in the variables that were only
seen to occur late in the disease process in reality occurred even later,
and more rapidly, than are illustrated in our figures.
Finally, on any given day, the mean values of the variables illus-
trated are based on an average of both observed and imputed values.
This makes it impossible to calculate appropriate confidence intervals
for the mean values illustrated in our graphs because calculation of
such would require independent real measurements, which was not
the case in the present study, causing an underestimation of the inter-
val sizes.
5 | CONCLUSIONS
Dogs with MMVD in ACVIM stage B212 experience increases in HR,
RR, RRR, and VHS, and decreases in BW and RT as they progress into
CHF. The change in VHS is characterized by a gradual increase over
time, whereas the other variables change within the last few months
before CHF. The variables with highest absolute change and rate of
change were RR and RRR. This finding reinforces the value of RR and
RRR as indicators of impending or incipient CHF. If RR and RRR are
routinely and frequently measured in dogs with stage B2 MMVD, it
may be possible for the onset of CHF to be detected earlier and
therefore for it to be managed sooner and more effectively.
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